Achaogen Data Show Rapid Rise in Rates of Resistance to Current Antibiotics; Illustrate Global Need for New, Well-Tolerated Agents to Address Varied Mechanisms of Resistance

SAN FRANCISCO & HELSINKI--(BUSINESS WIRE)--Achaogen, a clinical stage biopharmaceutical company addressing the issue of multi-drug resistant bacterial infections through the discovery and development of innovative broad-spectrum antibiotics, announced today the presentation of research on aminoglycoside (AG) resistance trends and comparative AG toxicities at the 19th Annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), being held May 16-19, 2009 in Helsinki, Finland.